After Hours Summary: KOPN +16.7%, HLF +15.2%, EA +3.9%, ANAD -21.5%, ZU -18.4%, NDLS -17.9% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: BRDR +102.1%, KOPN +16.7%, HLF +15.2%, PACB +12.4%, ICUI +11.6%, ACLS +10%, ZEN +9.4%, ZAGG +8%, PZZA +6.3%, MM +6.3%, ENPH +5.3%, FOSL +5.2%, QNST +5.1%, WPX +5.1%, TXMD +5%, LC +4.6%, EA +3.9%, CYH +3.8%, VRNG +3.6%, REXX +2.6%, FOLD +2.1%, ZLTQ +1.9%, VVUS +1.3%, HK +0.7%, TEG +0.7%, NVGS +0.7%, HRZN +0.3%, PBPB +0.2%
Companies trading higher in after hours in reaction to news: BRDR +102.7% (to be acquired by Pitney Bowes (PBI) for $14 per share in cash or ~$395 mln; co also reported earnings), MGI +37.1% (seeing reports that Western Union (WU) is in early talks to acquire the company), LOCM +13.6% (disclosed an amendment to Google Services Agreement; amendment provides for an extension of the agreement until March 31, 2018), PACB +12.4% (achieved second development milestone in clinical diagnostics agreement with Roche (RHHBY); $10 mln milestone payment brings total funding to date from RHHBY up to $55 mln), CYTX +5.6% (disclosed that on April 30, 2015, it entered into Amendment One to Joint Venture Termination Agreement with Olympus Corporation to extend its payment obligations under the Agreement), RTRX +4.3% (confirmed FDA Orphan Drug Designation for RE-024 for the treatment of Pantothenate Kinase-Associated Neurodegeneration)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: ANAD -21.5%, ZU -18.4%, NDLS -17.9%, ATRS -13%, TTGT -11.3%, SKUL -10.3%, TRUP -7.6%, TNET -7.1%, EVOL -5.6%, OCLR -5.3%, KONA -4.5%, CERS -3.8%, COUP -3.6%, OKE -3.3%, RUBI -2.9%, NFX -2.7%, GRPN -2.6%, SM -2.6%, CTLT -2.3%, FTR -1.9%, SAFT -1.9%, XXIA -1.9%, KGC -1.6%, SUPN -1.6%, MYGN -1.6%, SAND -1.5%, OKS -1.1%, WTW -1.1%, NWPX -1%, CLUB -0.9%
Companies trading lower in after hours in reaction to news: ARDX -25.6% (announced results from its Phase 2a clinical trial evaluating Tenapanor in Chronic Kidney disease patients; trial did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in treated patients), WLT -10.9% (discussed Going concern issues in 10-Q), ACHC -1.9% (priced 4.5 mln share public offering of common stock at $66.50 per share), ANTM -0.8% (announced a proposed public offering of $900 mln in equity units)